Andere talen Senti Biosciences, Inc.

Aandelen

SNTI

US81726A1007

slotkoers Nasdaq Andere beurzen 00:00:00 22-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,2809 ^USD	-8,65%		-6,37%	-57,44%

21/03	Senti Biosciences, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
21/03	Senti Biosciences, Inc. rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13/11
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China	06/11
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	06/11
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31-10-23
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting	31-10-23
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting	27-09-23
Senti Bio to Participate in Upcoming Conferences	26-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Senti Biosciences, Inc.

Aandelen

SNTI

US81726A1007

Andere talen

Filters